Gujarat Themis Biosyn share price
NSE: GUJTHEMBSE: 506879Pharmaceuticals & BiotechnologySmall Cap
Last close ₹324.00down ₹29.40 (8.32%)BSE ₹327.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹353.40.
52-week range of traded prices to 23 Oct 2026
₹225.05Low, 30 Mar 2026₹479.00High, 27 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,217 Cr886th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Aug 2026
- 86.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.21%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- 18.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 Jun 2026
- 0.56
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 9,32,72750.2% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 7 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹44 Crdown 1.00%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹11 Crup 1.61%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 25.3%
Revenue by year
Peak revenue ₹170 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 7 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 1 Aug | Sep 2025Filed 11 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 20 Jun | Jun 2026Filed 7 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.7 | 39.5 | 37.7 | 35.9 | 42.3 | 43.4 | 44.2 | 43.8 |
| Net profit | 10.6 | 13.0 | 12.0 | 9.1 | 14.3 | 12.5 | 10.9 | 11.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 30.4% | 32.8% | 31.8% | 25.3% | 33.7% | 28.7% | 24.6% | 25.3% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Not shown, EV/EBITDA: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 92% of 2,245 trading days since May 2017.
LowestHighest
Its median16.8Industry median28.1
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 98% of 2,399 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −19.2% | −4.5% | −15.8% | 0.3% |
Longer windows are left empty: a corporate action or price step on 2023-10-10 that cannot be sized sits inside this window.
Mutual funds holding it
12 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 4 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
- CutCut. Funds that held fewer shares than at the end of the month before.
- 2
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 6
| Fund | |||
|---|---|---|---|
 quant Small Cap Fundquant Mutual Fund | 54,37,833 | 0.59% | ₹210.8 Cr |
| quant Manufacturing Fundquant Mutual Fund | 9,96,000 | 5.42% | ₹38.6 Cr |
 Bank of India Small Cap FundBank of India Mutual Fund | 8,47,458 | 0.89% | ₹32.8 Cr |
| Bank of India Flexi Cap FundBank of India Mutual Fund | 7,06,215 | 0.88% | ₹27.4 Cr |
 Samco Multi Asset Allocation FundSamco Mutual Fund | 4,02,254 | 4.11% | ₹15.6 Cr |
| Bank of India Manufacturing & Infrastructure FundBank of India Mutual Fund | 2,82,486 | 1.11% | ₹10.9 Cr |
| Bank of India Multi Cap FundBank of India Mutual Fund | 2,82,486 | 0.81% | ₹10.9 Cr |
| Samco Active Momentum FundSamco Mutual Fund | 2,72,233 | 1.36% | ₹10.6 Cr |
| Quant Value Fundquant Mutual Fund | 2,58,000 | 0.52% | ₹10.0 Cr |
| quant Equity Savings Fundquant Mutual Fund | 1,18,644 | 7.69% | ₹4.60 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Gujarat Themis Biosyn in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 IOL Chemicals and PharmaceuticalsIOLCP | 4,818 | 28.7 | 2.7 | 15.3 | +18.6% | +60.1% | 9.6% | 11.8% | 0.61% |
 Novartis IndiaNOVARTIND | 4,505 | 46.1 | 5.5 | 37.7 | +5.4% | −4.9% | 12.2% | 12.2% | 0.00% |
 RPG Life SciencesRPGLIFE | 4,333 | 36.3 | 7.2 | 27.0 | +11.8% | −34.6% | 21.0% | 21.3% | 0.92% |
 Zota Health CareZOTA | 4,304 | – | 6.2 | 1,419.0 | +78.9% | – | −22.5% | −12.8% | 0.08% |
 Gufic BiosciencesGUFICBIO | 3,929 | 53.5 | 5.9 | 25.7 | +16.7% | +18.7% | 11.6% | 12.7% | 0.03% |
 SMS PharmaceuticalsSMSPHARMA | 3,883 | 37.8 | 4.9 | 24.3 | +10.2% | +40.4% | 14.4% | 11.5% | 0.10% |
 Kwality PharmaceuticalsKPL | 3,661 | 45.2 | 11.0 | 28.0 | +37.9% | +86.7% | 27.2% | 25.0% | 0.00% |
 Aarti DrugsAARTIDRUGS | 3,422 | 17.9 | 2.2 | 12.0 | +10.5% | +1.2% | 13.1% | 12.4% | 0.53% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹0.67 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.67 |
| 4 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.67 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
9 Oct · Rating
Sep 2026
30 Sep · Amendment to AOA/MOA
Gujarat Themis Biosyn share price by year
Each calendar year to 2025.Gujarat Themis Biosyn share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 441.65 | +44.6% | 469.90 | 212.20 |
| 2024BSE close | 305.45 | +19.1% | 518.40 | 269.15 |
| 2023BSE close | 256.55 | – | 256.55 | 180.65 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 10 Oct 2023.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 348.85 | 353.95 | 314.05 | 324.00 | 325.93 | 9,32,727 | 50.2% |
| 22 Oct 2026 | 347.85 | 367.90 | 337.95 | 353.40 | 349.61 | 4,78,950 | 53.0% |
| 21 Oct 2026 | 357.25 | 361.05 | 343.60 | 350.95 | 351.04 | 1,58,208 | 51.7% |
| 19 Oct 2026 | 367.65 | 372.20 | 357.00 | 358.65 | 362.65 | 89,208 | 62.8% |
| 16 Oct 2026 | 370.05 | 375.25 | 364.20 | 373.40 | 371.41 | 1,54,032 | 46.1% |
| 15 Oct 2026 | 385.90 | 385.90 | 367.00 | 370.05 | 375.04 | 1,32,226 | 61.8% |
| 14 Oct 2026 | 371.10 | 393.40 | 364.55 | 389.15 | 381.76 | 4,74,150 | 55.6% |
| 13 Oct 2026 | 369.00 | 376.85 | 351.00 | 373.00 | 363.94 | 3,21,043 | 56.2% |
| 12 Oct 2026 | 367.85 | 374.00 | 362.35 | 371.75 | 368.46 | 2,71,839 | 57.5% |
| 9 Oct 2026 | 368.05 | 373.60 | 359.60 | 363.50 | 366.32 | 3,91,458 | 52.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Offer for sale history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 9 Aug 2024 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 10 Oct 2023 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 3 Sep 2012 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- Legal name
- Gujarat Themis Biosyn Limited
- NSE symbol
- GUJTHEM
- BSE code
- 506879
- ISIN
- INE942C01045
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1984 on BSE, Feb 2025 on NSE
- Face value
- ₹1
- CIN
- L24230GJ1981PLC004878
- Corporate identity number, the registrar of companies' code for it